Trials / Completed
CompletedNCT02121080
Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 132 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This is a phase 1, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetic (PK) profile, and immunogenicity of REGN2222 ascending in cohorts of healthy adult volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN2222(SAR438584) | |
| DRUG | placebo |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2015-02-01
- Completion
- 2015-02-01
- First posted
- 2014-04-23
- Last updated
- 2015-03-11
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02121080. Inclusion in this directory is not an endorsement.